Premium
Mucocutaneous disorders in renal transplant recipients receiving sirolimus‐based immunosuppressive therapy: a prospective, case–control study
Author(s) -
Özcan Deren,
Seçkin Deniz,
Ada Simin,
Haberal Mehmet
Publication year - 2013
Publication title -
clinical transplantation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.918
H-Index - 76
eISSN - 1399-0012
pISSN - 0902-0063
DOI - 10.1111/ctr.12215
Subject(s) - medicine , mucocutaneous zone , dermatology , acne , sirolimus , seborrheic dermatitis , disease
Background Sirolimus ( SRL ) has some dermatologic complications including acneiform eruptions, edema, aphthous ulceration, and onychopathy. However, controlled studies reporting the prevalence and clinical characteristics of mucocutaneous disorders are scarce. Objective To investigate the prevalence and clinical spectrum of mucocutaneous disorders in renal transplant recipients ( RTR s) receiving SRL and to compare the findings with those in RTR s not receiving SRL . Methods Fifty RTR s (35 men, 15 women; mean age, 34.6 ± 11.6 yr) receiving SRL , 50 RTR s (36 men, 14 women; mean age, 34.4 ± 11.3 yr) not on SRL were screened for mucocutaneous disorders. Results In RTR s receiving SRL , skin infection (78%) was the most common dermatologic disorder followed by facial hyperpigmentation (50%) and acneiform eruption (46%). Herpes simplex virus infections (14%) and seborrheic dermatitis (38%) were significantly more common in RTR s on SRL (p < 0.05); the frequencies of edema, aphthous ulceration, acne, and longitudinal nail ridging were similar in both groups (p > 0.05). Limitations This study had a small sample size. The investigator was not blinded to immunosuppressive treatment protocols. Conclusion Renal transplant recipients receiving SRL are more likely to develop seborrheic dermatitis and herpes simplex virus infections than those not taking SRL . Whereas, they are not more prone to edema, aphthous ulceration, acne, or longitudinal nail ridging.